StocksMedium•29 October 2026•
1 min read
Bristol Myers Forecasts 2026 EPS of $6.35-$6.55 Amid Eliquis Revenue Warning
Key Facts
1Bristol Myers signals 2026 non-GAAP EPS guidance in the range of $6.35 to $6.55.
2The company is preparing for a $1.5B-$2B revenue step-down for its drug Eliquis in 2027.
Bristol Myers signals 2026 non-GAAP EPS guidance in the range of $6.35 to $6.55. Seeking Alpha reported that the company is preparing for a $1.5B-$2B revenue step-down for its drug Eliquis in 2027.
The long-term financial guidance aims to manage investor expectations regarding future impacts on key drug sales. This outlook suggests continued growth in the medium term despite pressures related to the anticipated loss of market exclusivity for core products in the coming years.